GenomeDx and Color to offer hereditary cancer risk genetic testing for prostate cancer
San Diego and Burlingame, CA – May 12, 2017 – GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced a collaboration with Color to offer its Color Test, a hereditary cancer risk genetic test that analyzes 30 genes. The collaboration further expands GenomeDx’s broad product offering across prostate cancer. The Color Test is intended to help patients diagnosed with prostate cancer understand the hereditary factors of their disease and the possible implications for their family members. In addition, the Color Test is intended to enable men who have a relative diagnosed with hereditary prostate cancer to determine if they are at higher risk for developing certain types of prostate cancer in the future.
Doug Dolginow, M.D., chief executive officer of GenomeDx, commented, “The collaboration with Color is consistent with GenomeDx’s goal to provide the best genomic and genetic solutions for patients afflicted with prostate cancer. Expanding our product offering with this hereditary cancer risk genetic test makes it easier for patients to access information about inherited risk for their families. In addition, data from the Color Test will be added to GenomeDx’s Decipher GRID research platform – aiding our research activities to discover and develop future cancer solutions.”
Othman Laraki, chief executive officer and co-founder of Color, added, “GenomeDx’s Decipher tests are an important tool for physicians and patients in the prostate cancer market, and we look forward to partnering with one of the scientific leaders in the field.”
Color is a health technology service that offers physician-ordered genetic testing for hereditary cancer risk. The Color Test analyzes 30 genes that impact the most common hereditary cancers, including prostate, breast, ovarian, colorectal, pancreatic, uterine, melanoma, and stomach cancers. To learn more about Color, follow Color on Twitter @Color or Facebook at facebook.com/Color and visit www.color.com
About Decipher GRID® and Cancer Classifier Tests
GenomeDx’s Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world’s largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.
Derived from GRID, GenomeDx’s Decipher Prostate and Bladder Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment.
About GenomeDx Biosciences
GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx’s Decipher Biopsy, Decipher Post-Op and Decipher Bladder are commercially available urologic cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient’s unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California.
Learn more at www.GenomeDx.com